Clinical Trials
67 trialsQuANTUM-WILD
Daiichi Sankyo
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Kura Oncology, Inc.
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Auto BMT for Non-M3 AML in 1st Remission in Pts </=60y of Age Using Busulfan/FTBI & VP16 as a Prep R
City of Hope Medical Center
QuANTUM-First
Daiichi Sankyo
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Risk-adapted Therapy for Primary Acute Myeloid Leukemia
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Interferon-alfa With or Without Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia
Eastern Cooperative Oncology Group
S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia
SWOG Cancer Research Network
AML1208
Gruppo Italiano Malattie EMatologiche dell'Adulto
APL0406
Gruppo Italiano Malattie EMatologiche dell'Adulto
Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia
Rush University Medical Center
Study of Idarubicin, Cytarabine, and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia
Jonsson Comprehensive Cancer Center
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
M.D. Anderson Cancer Center
LAL0904
Gruppo Italiano Malattie EMatologiche dell'Adulto
Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction
M.D. Anderson Cancer Center
Standard Idarubicin and Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)
M.D. Anderson Cancer Center
E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes
M.D. Anderson Cancer Center
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL
Nanfang Hospital, Southern Medical University
Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL
Nanfang Hospital, Southern Medical University
Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia
Massachusetts General Hospital
Lestaurtinib, Cytarabine, and Idarubicin in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
Children's Oncology Group
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
City of Hope Medical Center
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center
Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia
Children's Oncology Group
Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
Children's Oncology Group
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Roswell Park Cancer Institute
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia
Children's Oncology Group
Combination Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia
Children's Oncology Group
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphocytic Leukemia
National Cancer Institute (NCI)
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic Syndrome
Memorial Sloan Kettering Cancer Center
Monoclonal Antibody Therapy and Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia in Remission
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
National Cancer Institute (NCI)
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia
Columbia University
Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia
European Organisation for Research and Treatment of Cancer - EORTC